These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19704131)

  • 21. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
    Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
    J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
    Ly JK; Margot NA; MacArthur HL; Hung M; Miller MD; White KL
    Antivir Chem Chemother; 2007; 18(6):307-16. PubMed ID: 18320935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine.
    Lennerstrand J; Stammers DK; Larder BA
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2144-6. PubMed ID: 11408240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
    Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
    Lennerstrand J; Chu CK; Schinazi RF
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2078-84. PubMed ID: 17403997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
    White KL; Chen JM; Margot NA; Wrin T; Petropoulos CJ; Naeger LK; Swaminathan S; Miller MD
    Antimicrob Agents Chemother; 2004 Mar; 48(3):992-1003. PubMed ID: 14982794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M; López-Galíndez C
    Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
    Trivedi V; Von Lindern J; Montes-Walters M; Rojo DR; Shell EJ; Parkin N; O'Brien WA; Ferguson MR
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1291-300. PubMed ID: 18844463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
    Frankel FA; Marchand B; Turner D; Götte M; Wainberg MA
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2657-64. PubMed ID: 15980333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.
    Cong ME; Heneine W; García-Lerma JG
    J Virol; 2007 Mar; 81(6):3037-41. PubMed ID: 17192300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages.
    Bossi P; Yvon A; Mouroux M; Huraux JM; Agut H; Calvez V
    Res Virol; 1998; 149(6):355-61. PubMed ID: 9923011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.
    Álvarez M; Sebastián-Martín A; García-Marquina G; Menéndez-Arias L
    Sci Rep; 2017 Mar; 7():44834. PubMed ID: 28333133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.
    Matamoros T; Nevot M; Martínez MA; Menéndez-Arias L
    J Biol Chem; 2009 Nov; 284(47):32792-802. PubMed ID: 19801659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.